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The study1 published in this issue of Circulation Re-search showing that a null mutation of NHE-1 im-proves the tolerance of the heart to ischemia and
reperfusion (I/R) is an important contribution for the follow-
ing reasons: (1) In the animals with null mutation, contracture
during the ischemic period was less and ATP levels were
preserved compared with wild-type animals. This observa-
tion, on the one hand, provides evidence that protection by
downregulation of NHE-1 during the ischemic period itself is
indeed possible and, on the other hand, it argues against the
suggestion that the exchanger is inactive during this same
period.2 (2) In contrast with chronic blockade of the NHE-1
by pharmacological interventions,3 the long-term absence of
the exchanger does not elicit major compensatory changes
that, in turn, might negate the cardioprotective effect of
blocking its activity for a relative short term. This point is
related to a recent publication3 showing that long-term
treatment with the NHE-1 blocker cariporide is followed by
an upregulation of the functional units of the exchanger in a
similar way to the well-known tolerance phenomenon follow-
ing b-adrenergic receptor blockade. The absence of such
upregulation negates possible hypersensitivity to ischemia
upon withdrawal of the medication. The risk is evident in
hearts with upregulation of NHE-1, which gain Na1i more
rapidly during ischemia, and show impaired recovery after
reperfusion.4 (3) No additional protection was obtained by
adding the NHE-1 blocker eniporide to the NHE-1 null mice,
suggesting that there is not another NHE isoform that can be
blocked with this compound to add additional protection; the
findings additionally hint that the attenuation of the injury
obtained by the absence of the sarcolemmal NHE-1 is
maximal and, therefore, no further beneficial effect will be
detected by blocking the mitochondrial NHE (MNHE).
The classical explanation of the mechanism by which the
NHE-1 blockade protects against I/R is as follows. During
ischemia, a cytosolic acidosis of approximately 1 pH unit
occurs in about 10 minutes. This cytosolic acidosis stimulates
the NHE-1, increasing its activity and augmenting cytosolic
Na1 and Ca21 levels.5,6 Although other mechanisms could
contribute to the increase in intracellular Na1 (Na1i)7 during
ischemia, it has been shown that blockade of the NHE-1
before ischemia abolishes the increase in Na1i during this
period5,8 and diminishes the increase in cytosolic Na1 and
Ca21 during reperfusion.5,6 The increase in Ca21 secondary to
the increase in Na1 seems to be caused by the Na1-Ca21
exchanger (NCX) working in reverse mode,9 and cytosolic
Ca21 overload is a necrotic and apoptotic signal. Although
with some contradictory results, it has been possible to obtain
protection from I/R by blocking the NHE-1 or the NCX only
after the onset of reperfusion,10–12 suggesting that there is
protection against the reperfusion injury induced by these
mechanisms in addition to protection from the ischemic
injury.
Although other mechanisms can be operative,13 the activa-
tion of NHE-1 at the onset of reperfusion has been linked to
the increase in reactive oxygen species (ROS).14–16 This
exchanger reaches its maximal activity early after reperfu-
sion. It has been proposed that the increase in ROS leads to
activation of the mitogen-activated protein kinase pathway,
phosphorylating ERK1/2 and the cytosolic tail of the NHE-1,
increasing the exchanger activity.17 On the other hand, it has
been also reported that ERK1/2 mediates activation of the
Na1-HCO32 cotransport and that blockade of this mechanism
protects against I/R injury.18
The available evidence, therefore, establishes that the
cytosolic Ca21 overload induced by the NCX working in its
reverse mode can be prevented by blocking the NHE-1,
decreasing Na1i. A recent publication19 makes things more
difficult to interpret. In this study, the authors showed that
cariporide preserves mitochondrial proton gradient and de-
lays ATP depletion in mouse-derived myocytes (HL-1) after
simulated ischemia and suggested that these mitochondrial
changes are not secondary to changes in the cytosol. They
concluded that, during ischemia, cariporide acts at the mito-
chondrial level, delaying mitochondrial matrix acidification
and preserving ATP levels. They also suggested that the
prevention of mitochondrial Ca21 overload was not caripo-
ride’s mechanism of protection.
Mitochondrial NHE (MNHE) is apparently encoded by
NHE-6, with a molecular structure similar to that of NHE-
1.20–22 However, there are still some concerns about the
identification of the NHE-6 with the MNHE.21,22 The MNHE
can be blocked by several NHE blockers including caripo-
ride19,23,24; therefore, this drug blocks both the NHE-1 (sar-
colemmal) and the NHE-6 (mitochondrial) gene products.
In a more recent study,25 the effect of cariporide on cell
death induced by oxidative stress was examined in cultured
neonatal cardiomyocytes. The inhibitor suppressed cytosolic
Na1 and Ca21 accumulation and the loss of mitochondrial
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membrane potential induced by H2O2, while also decreasing
the mitochondrial Ca21 overload induced by H2O2. Despite
the decrease in cytosolic and mitochondrial Ca21 overload,
their results suggested a contribution of two Ca21-
independent pathways: calcium-independent cell death and
calcium-independent cytochrome c release induced by the
blocker. These results suggest that NHE-1 blockade preserves
mitochondrial integrity after oxidant stress. These actions
were not blunted by mitochondrial KATP channel blockers,
revealing different mechanisms of protection from those
operative in ischemic preconditioning. Although some studies
have suggested that NHE-1 inhibition and ischemic precon-
ditioning are linked phenomena, this25 and other studies26–29
provide evidence that this is not the case. Moreover, experi-
ments in isolated rat hearts comparing ischemic precondition-
ing with NHE inhibition showed that, although after reperfu-
sion protection was similar, only the NHE inhibition was able
to decrease the ischemic contracture.26
How can we reconcile the evidence that null mutation of
the NHE-1 induces protection from ischemia/reperfusion and
that cariporide also protects against ischemia/reperfusion but
acting on another isoform? The simplest explanation is that,
although the downregulation of the NHE-1 by its ablation by
genetic techniques protects the heart from ischemia/reperfu-
sion, additional protection can be obtained by the blockade of
MNHE (NHE-6) with the compound. However, the investi-
gators did not accomplish additional protection from I/R
when a blocker of the NHE-1, eniporide, was added to the
animals with the null mutation of the NHE-1. Among the
possibilities to understand this discrepancy, we should con-
sider the following: first, that NHE-1 is not only the sar-
colemmal isoform of the NHE but also the mitochondrial one;
second, that the genetic manipulation of these animals pro-
duced an unintentional downregulation or modification of the
MNHE, making it “inactive” for the ischemic/reperfusion
injury; third, that the attenuation of the injury obtained with
the blockade of the NHE-1 is maximal and so no further
beneficial effect will be detected blocking the MNHE.
New avenues of research begin with the novel contribu-
tions of these studies about the reperfusion injury process.
Should we consider the existence of two protections, one
during ischemia and the other one during reperfusion, each
mediated by a different NHE isoform? Is the acidification of
the cytosol a change that attenuates the reperfusion injury, in
contrast to the same change in the mitochondrial matrix?
What is the role of NCX in cytosol and mitochondrial Ca21
overload? May Ca21 overload in one compartment protect the
other? Should we consider the downregulation of the heart
NHE by genetic techniques a gene therapy possibility? All
are questions that should be answered in the near future.
In contrast with the promising results coming from studies
in several animal species and NHE inhibitors, clinical trials
have not shown unequivocal evidence of this protection. The
GUARDIAN,30 ESCAMI,31 and EXPEDITION32 trials are
examples of such disappointment. The latter was started in
2001 and stopped 6 months later for reasons unreleased to the
public. The strikingly beneficial effects of NHE inhibition in
well-controlled experimental systems give reason to hope that
future drug trials may prove the clinical utility of this
therapeutic principle.
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